Literature DB >> 17160471

Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis.

Govind K Makharia1, Vikas Sachdev, Rajiva Gupta, Suman Lal, R M Pandey.   

Abstract

The clinical, morphological, and histological features of intestinal tuberculosis (IT) and Crohn's disease (CD) mimic so much, that it becomes difficult to differentiate between them. The sensitivity of anti-Saccharomyces cerevisiae antibody (ASCA) IgG and ASCA IgA in CD is 60%-80%, whereas the specificity is almost 90%. There are no reports of study of ASCA in patients with IT, nor has it ever been used to differentiate CD from IT. Patients with ulcerative colitis (UC; n=25), CD (n=59), and IT (n=30) and 21 healthy controls were included in this study. The location and behavior of CD were classified according to the Modified Montreal classification. Five milliliters of blood was taken from them and serum was stored at -70 degrees C. ASCA antibodies (both IgG and IgA) were estimated using commercially available ELISA kits (AESKU Diagnostics, Germany). Anti-neutrophilic cytoplasmic antibody was measured by indirect immunofluorescence test. ASCA IgA was positive in 4.7%, 28%, 33.9%, and 43.3% and ASCA IgG was positive in 4.7%, 24%, 50.8%, and 46.6% of healthy controls and patients with UC, CD, and IT, respectively. Either ASCA IgG or ASCA IgA was positive in 9.5%, 40%, 61% and 66.6% of healthy controls, UC, CD, and IT, respectively. ANCA was positive in 0%, 32%, 10.1%, and 6.6% of healthy controls, UC, CD, and IT, respectively. ASCA IgG was positive in a significantly higher number of patients with CD (P<0.0001) and IT (P<0.0001) in comparison to healthy controls. ASCA IgA was positive in a significantly higher number of patients with UC (P<0.04), CD (P<0.013), and IT (P<0.006) in comparison to healthy controls. In comparisons between diseases, ASCA IgG was positive in significantly more patients with CD (P<0.001) and IT (P<0.001) in comparison to UC. There was no significant difference in ASCA IgA (33.9% vs. 43.3%), ASCA IgG (50.86% vs. 46.6%), or ANCA (10.7%, 7.4%) in patients with CD and IT, respectively. There was no correlation between ASCA and duration, location and behavior of CD, and IT. We conclude that ASCA IgG and ASCA IgA do not help to differentiate between IT and CD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160471     DOI: 10.1007/s10620-006-9527-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  39 in total

1.  Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

Authors:  S Vermeire; M Peeters; R Vlietinck; S Joossens; E Den Hond; V Bulteel; X Bossuyt; B Geypens; P Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2001-02       Impact factor: 5.325

2.  Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis.

Authors:  L F Flores-Suárez; J Cabiedes; A R Villa; F J van der Woude; J Alcocer-Varela
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

3.  Rising incidence and prevalence of Crohn's disease in Asia: is it apparent or real?

Authors:  Govind K Makharia
Journal:  J Gastroenterol Hepatol       Date:  2006-06       Impact factor: 4.029

4.  Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?

Authors:  R M Barnes; S Allan; C H Taylor-Robinson; R Finn; P M Johnson
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

5.  Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk.

Authors:  E J Irvine; J K Marshall
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

Review 6.  Does Crohn's disease need differentiation from tuberculosis?

Authors:  V Jayanthi; R J Robinson; S Malathi; B Rani; R Balambal; S Chari; K Taghuram; N Madanagopalan; J F Mayberry
Journal:  J Gastroenterol Hepatol       Date:  1996-02       Impact factor: 4.029

7.  Specific antibody response to oligomannosidic epitopes in Crohn's disease.

Authors:  B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

8.  Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease.

Authors:  Saleh A Naser; George Ghobrial; Claudia Romero; John F Valentine
Journal:  Lancet       Date:  2004 Sep 18-24       Impact factor: 79.321

9.  Differentiation between intestinal tuberculosis and Crohn's disease in endoscopic biopsy specimens by polymerase chain reaction.

Authors:  Hua Tian Gan; You Qin Chen; Qin Ouyang; Hong Bu; Xiu Ying Yang
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

Review 10.  Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease.

Authors:  Robert J Greenstein
Journal:  Lancet Infect Dis       Date:  2003-08       Impact factor: 25.071

View more
  21 in total

1.  Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis.

Authors:  Wahiba Sakly; Moncef Jeddi; Ibtissem Ghedira
Journal:  Dig Dis Sci       Date:  2007-11-30       Impact factor: 3.199

Review 2.  Advances in epidemiology and diagnosis of inflammatory bowel diseases.

Authors:  Sobia Ali; Cyrus P Tamboli
Journal:  Curr Gastroenterol Rep       Date:  2008-12

3.  An unusual case of gastric outlet obstruction caused by tuberculosis: challenges in diagnosis and treatment.

Authors:  Hari Padmanabhan; Alexander Rothnie; Pradip Singh
Journal:  BMJ Case Rep       Date:  2013-05-22

Review 4.  Differentiation of Crohn's disease from intestinal tuberculosis in India in 2010.

Authors:  Anna Benjamin Pulimood; Deepak Narayan Amarapurkar; Ujjala Ghoshal; Mathew Phillip; Cannanore Ganesh Pai; Duvvur Nageshwar Reddy; Birender Nagi; Balakrishna Siddhartha Ramakrishna
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

5.  Indian Society of Gastroenterology consensus statements on Crohn's disease in India.

Authors:  Balakrishnan S Ramakrishna; Govind K Makharia; Vineet Ahuja; Uday C Ghoshal; Venkataraman Jayanthi; Benjamin Perakath; Philip Abraham; Deepak K Bhasin; Shobna J Bhatia; Gourdas Choudhuri; Sunil Dadhich; Devendra Desai; Bhaba Dev Goswami; Sanjeev K Issar; Ajay K Jain; Rakesh Kochhar; Goundappa Loganathan; Sri Prakash Misra; C Ganesh Pai; Sujoy Pal; Mathew Philip; Anna Pulimood; Amarender S Puri; Gautam Ray; Shivaram P Singh; Ajit Sood; Venkatraman Subramanian
Journal:  Indian J Gastroenterol       Date:  2015-03-14

Review 6.  Meta-Analytic Bayesian Model For Differentiating Intestinal Tuberculosis from Crohn's Disease.

Authors:  Julajak Limsrivilai; Andrew B Shreiner; Ananya Pongpaibul; Charlie Laohapand; Rewat Boonanuwat; Nonthalee Pausawasdi; Supot Pongprasobchai; Sathaporn Manatsathit; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2017-01-03       Impact factor: 10.864

7.  Fecal polymerase chain reaction for Mycobacterium tuberculosis IS6110 to distinguish Crohn's disease from intestinal tuberculosis.

Authors:  Balamurugan Ramadass; Sucharita Chittaranjan; Venkataraman Subramanian; Balakrishnan S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2010-06-25

8.  Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.

Authors:  Shulan Zhang; Jing Luo; Ziyan Wu; Dirk Roggenbuck; Peter Schierack; Dirk Reinhold; Ji Li; Xiaofeng Zeng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Clin Transl Gastroenterol       Date:  2018-02-15       Impact factor: 4.488

9.  Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent.

Authors:  Deepak N Amarapurkar; Nikhil D Patel; Priyamvada S Rane
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

10.  Anti Saccharomyces cerevisiae Antibodies in Patients With Anti-β2 Glycoprotein I Antibodies.

Authors:  Amani Mankaï; Skander Layouni; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.